BCL2 and B-cell non-Hodgkin lymphoma: In high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, nivolumab consolidation after DA-EPOCH-R induction was well tolerated and showed 61% CMR [81].